Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Diabetes, Obesity & Metabolism|March 25, 2022
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery diseaseSubodh Verma, Mohammed Al-Omran, Lawrence A Leiter, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 6, 2020
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney DiseaseJohannes F E Mann, Vivian A Fonseca, Neil R Poulter, et al.
Skeletal Radiology|April 23, 2025
Radiographic findings in patients suspected of subacromial impingement syndrome in relation to shoulder pain and disabilityLinda Christie Andrea, Susanne Wulff Svendsen, Poul Frost, et al.
Diabetes, Obesity & Metabolism|May 19, 2021
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysisJohannes F E Mann, John B Buse, Thomas Idorn, et al.
Diabetes, Obesity & Metabolism|November 25, 2025
Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist useTina Vilsbøll, Michael Stellfeld, Vanita R Aroda, et al.
Medical Care|December 29, 2007
Hospital variation in use of secondary preventive medicine after discharge for first acute myocardial infarction during 1995-2004Søren Rasmussen, Steen Z Abildstrom, Jeppe N Rasmussen, et al.
Journal of Epidemiology and Community Health|March 16, 2006
Mortality after acute myocardial infarction according to income and educationJeppe N Rasmussen, Søren Rasmussen, Gunnar H Gislason, et al.
Stroke|May 18, 2022
Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6W David Strain, Ofir Frenkel, Martin A James, et al.
Diabetes, Obesity & Metabolism|October 19, 2020
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trialLinong Ji, Xiaolin Dong, Yiming Li, et al.
British Journal of Clinical Pharmacology|August 23, 2007
Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarctionMorten L Hansen, Gunnar H Gislason, Lars Køber, et al.
Pageof 11